D. Castro-Diaz

发表

Guidelines on neurogenic lower urinary tract dysfunction.

G. Kramer, J. Wyndaele, A. Mattiasson, 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

EAU guidelines on neurogenic lower urinary tract dysfunction.

J. Pannek, B. Blok, G. Kramer, 2009, European urology.

Evaluation of the impact of the urinary symptoms on quality of life of patients with painful bladder syndrome/chronic pelvic pain and radiation cystitis: EURCIS study

D. Castro-Diaz, M. Rapariz-González, D. Mejía-Rendón, 2014 .

Evaluation of the impact of the urinary symptoms on quality of life of patients with painful bladder syndrome/chronic pelvic pain and radiation cystitis: EURCIS study.

D. Castro-Diaz, M. Rapariz-González, D. Mejía-Rendón, 2014, Actas urologicas espanolas.

What is the utility of urodynamics, including ambulatory, and 24 h monitoring, in predicting upper urinary tract damage in neuro‐urological patients and other lower urinary tract dysfunction? ICI‐RS 2017

L. Cardozo, J. Djurhuus, M. Averbeck, 2018, Neurourology and urodynamics.

Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence.

S. MacNeil, F. Montorsi, F. Burkhard, 2017, European urology.

Long‐term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: A systematic review

J. Pannek, G. Karsenty, T. Kessler, 2017, Neurourology and urodynamics.

Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)

M. Wehling, M. Oelke, E. Chartier-Kastler, 2015, Age and ageing.

Overactive bladder: Is there a link to the metabolic syndrome in men?

H. Kölbl, L. Cardozo, P. van Kerrebroeck, 2010, Neurourology and urodynamics.

The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials

S. Mujais, M. B. Blauwet, C. Chapple, 2015, Quality of Life Research.

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

M. Stölzel, Jeffrey Frankel, S. Herschorn, 2013, Urology.

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

D. Castro-Diaz, J. Rejas, I. Lizarraga, 2012, BMC Urology.

Management of Female and Functional Urology Patients During the COVID Pandemic

R. Dmochowski, B. Peyronnet, E. Chartier-Kastler, 2020, European Urology Focus.

Exercise, diet and weight loss before therapy for lower urinary tract symptoms/benign prostatic hyperplasia?

D. Castro-Diaz, D. Castro-Díaz, 2015, BJU international.